Immunoregulatory kinases and T-cell pathways in DNA-damage response and autoimmune inflammation: Emerging roles of BUB1 and IGFL2
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2026.116509 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Sarad Pawar Naik Bukke und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical Technology, Kampala International University, Western Campus, P.O. Box 71, Ishaka, Bushenyi, Uganda. E…. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, DNA Damage, T-Lymphocytes, Autoimmune Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 137 Literaturangaben.
Abstract (Originalsprache)
The DNA damage response (DDR) is considered a pivotal regulator of immune activation, in which genomic stress serves as an interface between genomic biochemistry and innate and adaptive immunity. Recent discoveries have shown that the mitotic kinase BUB1 has non-canonical cytoplasmic roles, including regulating the accumulation and recognition of endogenous double-stranded RNA (dsRNA) generated under stress conditions of genotoxicity. BUB1 increases type I interferon signalling via RIG-I/MDA5 and controls cytokine production, interferon-stimulated gene transcription, and antitumor immune surveillance, particularly after radiotherapy, but also promotes persistent inflammation by perpetuating signalling. In addition, insulin-like growth factor-like family 2 (IGFL2), secreted by activated and exhausted T-cells, has been identified as a potent mediator of the T-cell-monocyte-fibroblast crosstalk that drives inflammatory myeloid programming, fibroblast activation, and tissue regeneration. This sensing of BUB1-regulated expression of the extracellular (dsRNA) and the stromal remodelling mediated by IGFL2 can be considered a pathogenic interface between DDR activation and the inflammatory response of the maladaptive immune response. These revelations ensure that BUB1 and IGFL2 are core immunoregulatory nodes upon which therapeutic actions are understood in accurate oncology, immunotherapy, and the control of autoimmune diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics and Pharmaceutical Technology, Kampala International University, Western Campus, P.O. Box 71, Ishaka, Bushenyi, Uganda. Electronic address: drsaradpawar@gmail.com.
- Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas University, Adamas University, Barbaria, West Bengal 700126, India.
- Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh 201310, India.
- Faculty of Pharmaceutical Science, Assam down town University (AdtU), Guwahati 781026, Assam, India.
- Department of Biotechnology, Pasteur Institute of Iran (IPI), Tehran Province, Tehran, District 11, Rajabi, M9RW+M55, Iran.
- Department of Clinical Pharmacy and Pharmacy Practice, Kampala International University, Western Campus, P.O. Box 71, Ishaka, Bushenyi, Uganda.
Zitieren
APA
Bukke, S. P. N., Chettupalli, A. K., Sharma, C. B., Thalluri, C., Eftekhari, Z., & Yadesa, T. M. (2026). Immunoregulatory kinases and T-cell pathways in DNA-damage response and autoimmune inflammation: Emerging roles of BUB1 and IGFL2. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.116509
Vancouver
Bukke SPN, Chettupalli AK, Sharma CB, Thalluri C, Eftekhari Z, Yadesa TM. Immunoregulatory kinases and T-cell pathways in DNA-damage response and autoimmune inflammation: Emerging roles of BUB1 and IGFL2. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.116509
BibTeX
@article{Bukke2026,
author = {Bukke, Sarad Pawar Naik and Chettupalli, Ananda Kumar and Sharma, Chetan Banbarilal and Thalluri, Chandrashekar and Eftekhari, Zohre and Yadesa, Tadele Mekuriya},
title = {Immunoregulatory kinases and T-cell pathways in DNA-damage response and autoimmune inflammation: Emerging roles of BUB1 and IGFL2},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2026.116509}
}
EUVIMED